AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06629324 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Rehabilitation methods involve various therapies tailored to the patient\&#39;s mobility level. (1) Physical therapy focuses on exercises to control the head, neck, and trunk, manage muscle tone, and reduce spasticity. Patients gradually practice essential movements like rolling, sitting, crawling, standing, and walking, aligned with developmental milestones. (2) Occupational therapy aims to enhance fine motor skills and daily activities. Through hand function exercises, patients improve upper limb functionality, strengthen their ability to grasp and hold objects and refine coordination between both hands and hand-eye coordination. (3) Speech therapy improves communication, cognitive abilities, and chewing and swallowing functions. Specific exercises target lip and mouth movements, helping patients express and understand language better. Additionally, there are activities to strengthen jaw and facial muscles, which are essential for improving chewing and swallowing abilities.
Study NCT06629324 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation
Description: Rehabilitation methods involve various therapies tailored to the patient\&#39;s mobility level. (1) Physical therapy focuses on exercises to control the head, neck, and trunk, manage muscle tone, and reduce spasticity. Patients gradually practice essential movements like rolling, sitting, crawling, standing, and walking, aligned with developmental milestones. (2) Occupational therapy aims to enhance fine motor skills and daily activities. Through hand function exercises, patients improve upper limb functionality, strengthen their ability to grasp and hold objects and refine coordination between both hands and hand-eye coordination. (3) Speech therapy improves communication, cognitive abilities, and chewing and swallowing functions. Specific exercises target lip and mouth movements, helping patients express and understand language better. Additionally, there are activities to strengthen jaw and facial muscles, which are essential for improving chewing and swallowing abilities.
Study NCT06713941 — intervention group
Intervention type: OTHER
Intervention: Study of the treatment
Description: Intervention Description 1 \* (Limit: 1000 characters) Study of prescribed treatments, treatments taken by the patients, and treatment discontinuation
Study NCT06172660 — intervention group
Intervention type: DRUG
Intervention: Nirsevimab
Description: Immunoprophylaxis against RSV
Study NCT05737550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Previct Drugs
Description: Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.
Study NCT05664581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid Acoustic Pulse
Description: Subcutaneous Rapid Acoustic Pulse Treatments
Study NCT05554692 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic tests of cochlear implant function
Description: Because the subjects in the study will use CI devices that they have already received as part of their standard-of-care treatment, the medical device itself is not an intervention for the purposes of this study. The intervention here will be to carry out diagnostic tests of CI function. This will include perceptual tests of temporal discrimination and speech understanding.
Study NCT05554692 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnostic tests of auditory function
Description: The intervention here will be to carry out diagnostic tests of hearing. This will include perceptual tests of temporal discrimination and speech understanding.
Study NCT04820621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Runcaciguat (BAY1101042)
Description: Given as 1 x 15 mg modified release \[MR\] tablet
Study NCT06750068 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional space maintainer
Description: Stainless steel space maintains
Study NCT05746117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aktiia Device
Description: The Aktiia Bracelet is a CE-marked medical device that will be used in accordance with its instructions for use. The bracelet non-invasively measures optical signals at the wrist, which are used to determine blood pressure. The bracelet comes with a bluetooth enabled upper arm cuff that can be used to take on-demand blood pressure measurements. All measurements are transmitted to a dashboard that a clinical pharmacist monitors during the participant's enrollment in the study.
Study NCT05746117 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upper arm cuff
Description: A standard upper arm oscillometric cuff that can be used to take blood pressure at home.
Study NCT05486832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiovalve TR valve replacement System
Description: The Cardiovalve system includes a valve and delivery system, designed for replacement of the tricuspid valve through a transcatheter.
Study NCT05187741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile health (mHealth)
Description: A message will be sent on Monday and Friday at 9:00 am for 3 months, the first day they will receive a message focused on adherence and the second day a message focused on motivation. Subsequently, a message will be sent on Mondays for 3 more months.~Reminders for appointments with your treating physician will be sent during the entire intervention period (6 months).
Study NCT05044663 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study
Study NCT05285072 — intervention group
Intervention type: RADIATION
Intervention: PET-CT scan
Description: PET-CT scan using 68Ga-DFO
Study NCT06365112 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy assisted
Description: Endoscopy
Study NCT01353482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin (75mg/m2 iv) wil be administered on day one of a 21 day cycle for up to 6 cycles
Study NCT06748482 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counseling
Description: a 15-minute-consultation session with the clinical pharmacist will include detailed and personalized advice on how each patient should take his prescribed medications, the best time to take them, the possible drug-drug interactions, the possible adverse effects such as post operative nausea and vomiting (PONV), bleeding, fever and infection and the required action. A written paper outlining the main points including the detailed protocol with times and doses will be handed to the patient at the end of the consultation. Moreover, a recorded voice note with the detailed protocol will be sent to the patients via the WhatsApp application
Study NCT01353482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin (75mg/m2 iv) wil be administered on day one of a 21 day cycle for up to 6 cycles
Study NCT01353482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Patients will be given Pemetrexed (500mg/m2 iv) on day one of a 21 day cycle for up to 6 cycles
Study NCT01353482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Patients will be given Pemetrexed (500mg/m2 iv) on day one of a 21 day cycle for up to 6 cycles
Study NCT01353482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorinostat
Description: The dose and frequency of vorinostat will be determined in the Phase I study. Vorinostat will be given concurrently with Cisplatin/Pemetrexed.
Study NCT01353482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomised into the placebo arm of the trial will receive Cisplatin and Pemetrexed as standard as well as placebo.
Study NCT05198089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Use MyInspiration website
Study NCT05256277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT101a
Description: cytokine-induced memory-like NK cells
Study NCT05493865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Parent-Child Single-Session-intervention of Mindset Intelligence, Failure and Emotion (PC-SMILE)
Description: This study will be a three-arm cluster-randomised controlled trial to examine the efficacy of the PC-SMILE for adolescents by comparing to a C-SMILE intervention group and a no-intervention waitlist control group.
Study NCT06434103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921；Adebrelimab；SHR-8068；carboplatin
Description: SHR-A1921:Specified dose on specified days. SHR-8068: Specified dose on specified days. Adebrelimab: Specified dose on specified days. Carboplatin:Specified dose on specified days.
Study NCT04741529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program app
Description: The HMP app was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on the work of Drs. Richard Davidson and Cortland Dahl. HMP is designed to promote and protect psychological well-being through sustainable skills training. The program is grounded in constituents of psychological well-being identified in empirical literature. HMP provides core content, with instruction administered through a curriculum of high-quality guided practices. HMP is based on research on eudaimonic well-being (e.g., environmental mastery, purpose) and brain-based skills that underlie these qualities (e.g., regulation of attention, mental flexibility). HMP has >100 guided audio practices that address 4 constituents of well-being: awareness, connection, insight, and purpose.~Participants in this study will receive 2 weeks of training in the Connection module of HMP.
Study NCT04941131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate, povidone iodine
Description: This is a mouth wash that can be used over the counter.
Study NCT06749262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking on incline or walking at increasing speed for 36 visits
Description: Subjects will be prepared for data collection by wearing an exercise suit and obtaining height and body weight. Breathing sensors and foot switches will be worn to measure breathing and walking performance.
Study NCT06750744 — intervention group
Intervention type: RADIATION
Intervention: chest x ray
Description: chest X ray identify severity of pneumonia
Study NCT06750744 — intervention group
Intervention type: RADIATION
Intervention: chest X ray
Description: chest radiological evaluation via x ray
Study NCT06750744 — intervention group
Intervention type: DRUG
Intervention: Tigecycline (Tygacil)
Description: selective antibiogram
Study NCT06748846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physiotherapy + Occupational therapy + Focal Muscle Vibration
Description: - Physiotherapy (60 minutes): Includes active strengthening of antagonist muscles, mobilization, stretching of cervical-thoracic kinetic chains, proprioceptive control, postural exercises, and body schema modulation. -Occupational Therapy (30 minutes): Focuses on improving proprioceptive, praxis, and spatial control of movements. -SMV (15 minutes): Administered during the last part of each physiotherapy session. Experimental Group: SMV is applied to the trapezius (middle/descending fibers) and quadratus lumborum bilaterally at 80 Hz with an amplitude of 0.5 mm.
Study NCT06748846 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Physiotherapy + Occupational therapy + Sham Focal Muscle Vibration
Description: Physiotherapy (60 minutes): Includes active strengthening of antagonist muscles, mobilization, stretching of cervical-thoracic kinetic chains, proprioceptive control, postural exercises, and body schema modulation. Occupational Therapy (30 minutes): Focuses on improving proprioceptive, praxis, and spatial control of movements. SMV (15 minutes): Administered during the last part of each physiotherapy session. Control Group: Sham SMV using disconnected terminals produces sound but no vibration, ensuring blinding.
Study NCT06748651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allocetra
Description: Intra-articular injection of Allocetra performed once on Day 1 of the study
Study NCT06749730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: adepelizumab ,1200mg, q3w
Study NCT06749730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: apatinib，250mg，QD
Study NCT06749730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin
Description: cisplatin 25mg/m2，gemcitabine 1000mg/m2 d1,d8，q3w
Study NCT06748339 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT06750939 — intervention group
Intervention type: OTHER
Intervention: propofol
Description: The hemodynamic effects of propofol and ketamine are well-documented in the general patient population, yet the incidence and characteristics of cardiovascular collapse induced by these agents in critically ill patients remain underexplored. Cardiovascular collapse, a severe and potentially life-threatening event, may arise due to the unique physiological stressors present in the critical care setting, including pre-existing hemodynamic instability, comorbidities, and the administration of high-risk pharmacological agents. Despite the theoretical understanding of these drugs' pharmacodynamics, there is limited evidence assessing their differential impact on cardiovascular function in this vulnerable population.~This study aims to contribute novel insights to the literature by exploring the association between these widely used sedative-hypnotic agents and the development of cardiovascular collapse. While propofol is known for its potent vasodilatory and myocardial depressive effects,
Study NCT05190588 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mesotherapy
Description: Mesotherapy (MT) Sterile and disposable (0.26mm × 4mm and 0.3mm × 13 mm, Terumo) will be used. Patients will receive 2 ml of 2% lidocaine, 2 ml of pentoxifylline and will be used. Injection techniques (IDP=2-4 MM) AND (IDS=1-2 MM) will be used.
Study NCT06442280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin tablet
Description: Dapagliflozin 10 mg 1 tablet once daily
Study NCT06442280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin tablet
Description: Dapagliflozin 10 mg 1 tablet once daily
Study NCT06442280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline Solution, 1 Ml
Description: Intravenous infusion of furosemide combined with hypertonic saline solutions (100 mL) twice daily
Study NCT06442280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hypertonic Saline Solution, 1 Ml
Description: Intravenous infusion of furosemide combined with hypertonic saline solutions (100 mL) twice daily
Study NCT06442280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide Injection
Description: Furosemide 20 mg
Study NCT06442280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Furosemide Injection
Description: Furosemide 20 mg
Study NCT05757596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VSA001 injection
Description: The active drug is VSA001 injection. The active pharmaceutical ingredient (API) contained in VSA001 is a synthetic, double-stranded, hepatocyte targeted NAG-conjugated RNAi.
Study NCT05757596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Saline, volume matched
Study NCT06750939 — intervention group
Intervention type: OTHER
Intervention: ketamine
Description: The hemodynamic effects of propofol and ketamine are well-documented in the general patient population, yet the incidence and characteristics of cardiovascular collapse induced by these agents in critically ill patients remain underexplored. Cardiovascular collapse, a severe and potentially life-threatening event, may arise due to the unique physiological stressors present in the critical care setting, including pre-existing hemodynamic instability, comorbidities, and the administration of high-risk pharmacological agents. Despite the theoretical understanding of these drugs' pharmacodynamics, there is limited evidence assessing their differential impact on cardiovascular function in this vulnerable population.~This study aims to contribute novel insights to the literature by exploring the association between these widely used sedative-hypnotic agents and the development of cardiovascular collapse. While propofol is known for its potent vasodilatory and myocardial depressive effects,
Study NCT06751030 — intervention group
Intervention type: BEHAVIORAL
Intervention: The Mother Mentor program
Description: The MOther MENTor (MoMent) program in Nigeria pairs trained treatment-experienced Women living with HIV (WLWH), known as Mentor Mothers (MMs), with new mothers who are newly diagnosed with HIV to improve access to and retention in HIV care
Study NCT06189690 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Repetitive TMS will be administered by a MagPro R30 stimulator and an active/placebo MCF-B70 A/P coil. All participants will use two surface electrodes to simulate rTMS skin sensations near to stimulation site. rTMS/sham conditions will be double-blinded by a USB stick. The USB contains the information about rTMS/sham condition and this is not available to the stimulator operator. Parameters of rTMS were previously described.
Study NCT06751030 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: GeneXpert HPV test
Description: A cervical cancer screening tool.
Study NCT06749886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab, 120 mg subcutaneous injection, every 21-28 days a cycle, given on the first day, a loading dose is given on d8 of the first cycle, and continued use
Study NCT06749886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: Tislelizumab, 200 mg intravenous infusion, every 21 days a cycle, given on the first day, and continued use
Study NCT06749886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel, 60 mg/m2 intravenous infusion, every 21 days a cycle, given on the first day, and continued use.
Study NCT06748742 — intervention group
Intervention type: DRUG
Intervention: In robot-assisted radical prostatectomy, indocyanine green fluorescent solution is injected through the urethra, and the position and structure of the urethra are observed by the device
Description: In robot-assisted radical prostatectomy, indocyanine green fluorescent solution is injected through the urethra, and the position and structure of the urethra are observed by using the fluorescence imaging equipment that comes with the device. Guided by real-time fluorescence imaging, the urethra is precisely dissected and severed in front of the bladder neck. Through this improved operation, the bladder neck is protected, the neck injury that is common in conventional surgical operations is reduced, and the reconstructive surgical operations necessary after loss are reduced, and the surgical efficiency is improved. By protecting the bladder neck, the sphincter is better preserved, postoperative urinary incontinence is reduced, and the surgical outcome is improved.
Study NCT06750237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stable surface and Isometrics
Description: will be treated by training the patients on unstable surfaces. The heating pad will be applied for 10 minutes as a warm-up. Then Isometric exercises of the lower limb and bridging for back extensors strengthening and improving patient confidence will be done. After that Single leg stance, Toe Raises, standing lower limb abduction and extension with proper support will be done and Mini Squats by stabilizing the patient against the wall or taking the help of an attendant or through a Stabilizing belt will be done. The session will last for 30 minutes. It will be conducted 2 months 3 times per week
Study NCT06750237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unstable surface and isometrics
Description: and will be treated by training the patients on stable surfaces. The heating pad will be applied for 10 minutes as a warm-up. Then Isometric exercises of the lower limb and bridging for back extensors strengthening and improving patient confidence will be done. After that Single leg stance, Toe Raises, standing lower limb abduction and extension with proper support will be done and Mini Squats by stabilizing the patient against the wall or taking the help of an attendant or through a Stabilizing belt will be done. The session will last for 30 minutes. It will be conducted 2 months 3 times per week.
Study NCT06751394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody (Toripalimab)
Description: PD-1 antibody: (Toripalimab): 240mg q3w
Study NCT06751394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine:1000mg/m² d1-14 q3w; Capecitabine:825mg/m² on the day of radiotherapy
Study NCT06751394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m² q3w
Study NCT06751394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 200 mg/m² q3w
Study NCT06751394 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 45-50Gy/25Fx or 30Gy/15Fx
Study NCT06751394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: The type of surgery will depend on the site of recurrence and the involvement of adjacent structures, which will be determined by the surgeons.